Express Mail No. EL 451 600 441 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of: Dasseux, et al.

Confirmation No.: 9219

Application No.: 09/465,718

Group Art Unit: 1631

Filed: December 17, 1999

Examiner: Borin, M.

For:

APOLIPOPROTEIN A-I AGONISTS

AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

Attorney Docket No.: 9196-018-999

FEE TRANSMITTAL SHEET

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

The claim amendment fee has been estimated as shown below:

	(Col. 1)0 CLAIMS REMAINING AFTER AMENDMENT		(Col. 2)	(Col. 3)	SMALL ENTITY			OTHER THAN A SMALL ENTIT			
			HIGHEST NO. PREVIOUSLY PAID	PRESENT EXTRA	RATE		ADDIT. FEE	OR	RATE	IAN A S.	ADDIT. FEE
TOTAL		MINUS	62	0	x 9						
INDEP.	1 1	MINUS	3	0	x 42				x 18 x 84		0.00
	DD DG = -					\$			X 04	<u>s</u>	0.00
LJ FIRST	PRESENTATI	ON OF M	MULTIPLE DEP. CLAIM	1	TOTAL	\$		OR	TOTAL	\$	0.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted.

Date:

June 11, 2003

42,983 (Reg. No.)

Rahul Pathak

For Laura A. Coruzzi (Reg. No. 30,742) PENNIE & EDMONDS LLP

1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090

Enclosure



EXPRESS MAIL NO.: EL 451 600 441 US HONER LEWISON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux et al.

Confirmation No.: 9219

Application No.: 09/465,718

Group Art Unit: 1631

Filed: December 17, 1999

Examiner: Borin, M.

For: APOLIPOPROTEIN A-I AGONISTS

Attorney Docket No.: 9196-018-999

AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants have carefully considered the non-final Office Action mailed March 11, 2003, in connection with the above-captioned Application. Reconsideration of the claims in light of the amendment and remarks that follow is respectfully requested. Filed herewith are Exhibits A (Claim Amendment: Pending Claims), B (Notice of Recordation of Assignment of U.S. Application No. 08/940,096) and C (Notice of Recordation of Assignment of U.S. Application No. 08/940,093) an Amendment Fee Sheet, a Terminal Disclaimer and Terminal Disclaimer Fee Sheet.

AMENDMENT

IN THE CLAIMS

Please cancel Claims 10, 11, 76, 77 and 78 without prejudice.